TSVT * Stock Overview
A cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
2seventy bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$170.00 |
| 52 Week High | US$347.00 |
| 52 Week Low | US$167.00 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | -69.26% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -80.09% |
Recent News & Updates
Recent updates
Shareholder Returns
| TSVT * | MX Biotechs | MX Market | |
|---|---|---|---|
| 7D | 0% | 0% | 0% |
| 1Y | -69.3% | 0% | 0% |
Return vs Industry: TSVT * underperformed the MX Biotechs industry which returned -6% over the past year.
Return vs Market: TSVT * underperformed the MX Market which returned 3.7% over the past year.
Price Volatility
| TSVT * volatility | |
|---|---|
| TSVT * Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in MX Market | 0% |
| 10% least volatile stocks in MX Market | 0% |
Stable Share Price: TSVT * has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine TSVT *'s volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2021 | 425 | Nick Leschly | www.2seventybio.com |
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company’s products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and chimeric antigen receptor-T cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol-Myers Squibb Company.
2seventy bio, Inc. Fundamentals Summary
| TSVT * fundamental statistics | |
|---|---|
| Market cap | Mex$5.89b |
| Earnings (TTM) | -Mex$3.64b |
| Revenue (TTM) | Mex$2.11b |
2.8x
P/S Ratio-1.6x
P/E RatioIs TSVT * overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TSVT * income statement (TTM) | |
|---|---|
| Revenue | US$124.69m |
| Cost of Revenue | US$272.99m |
| Gross Profit | -US$148.30m |
| Other Expenses | US$67.16m |
| Earnings | -US$215.46m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
Aug 14, 2023
| Earnings per share (EPS) | -4.29 |
| Gross Margin | -118.94% |
| Net Profit Margin | -172.80% |
| Debt/Equity Ratio | 0% |
How did TSVT * perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/08/02 07:00 |
| End of Day Share Price | 2023/05/05 00:00 |
| Earnings | 2023/03/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
2seventy bio, Inc. is covered by 8 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| John Newman | Canaccord Genuity |
| Samantha Lynn Semenkow | Citigroup Inc |
| Samantha Lynn Semenkow | Citigroup Inc |